欧普康视科技股份有限公司 关于医疗器械生产许可证变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"）于近日收到安徽省药品监 督管理局换发的《医疗器械生产许可证》（许可证编号：皖药监械生产许 20150064 号），完成了医疗器械生产许可变更登记。本次变更主要涉及生产地址增加"合 肥市高新区望江西路 4899 号 1#C 楼 1 层"和生产范围增加"08-05 呼吸、麻醉、 急救设备辅助装置"。具体情况如下： 一、《医疗器械生产许可证》基本情况 证券代码：300595 证券简称：欧普康视 公告编号：2025-083 8、许可期限：自 2025 年 10 月 9 日至 2030 年 7 月 23 日 9、发证部门：安徽省药品监督管理局 10、发证时间：2025 年 10 月 9 日 二、对公司的影响及风险提示 1、许可证编号：皖药监械生产许 20150064 号 2、统一社会信用代码：91340100723323559X 3、企业名称：欧普康视科技股份有限公司 4、法定代表人/企业负责人：陶悦群 5、住所：合肥市 ...

Group 1: Industry Overview - The medical device market in China is experiencing rapid growth, with the market size projected to increase from 440.3 billion yuan in 2017 to 1,154.4 billion yuan by 2024, representing a compound annual growth rate (CAGR) of 14.76%, significantly higher than the global CAGR of 4.82% during the same period [2] - By 2025, the market size is expected to reach 1.24 trillion yuan, and by 2030, it is anticipated to exceed 1.66 trillion yuan, driven by government support and increasing per capita medical spending [2] - The establishment of the Anhui Medical Device Innovation Alliance aims to enhance collaboration within the industry and promote the development of high-end medical imaging equipment [2] Group 2: Company Developments - Companies in the medical device sector are focusing on high-end product development, with significant investments in research and development [4] - Opcon Vision has successfully developed a high-permeability oxygen material, DK185, which exceeds industry standards, leading to the launch of new products such as corneal reshaping lenses [4] - Anhui Zhongke Ion Medical Technology Equipment Co., Ltd. has created China's first and the world's most compact superconducting proton therapy system, with a domestic production rate of over 95%, currently in clinical trial [4] - Anhui Tongling Bionic Technology Co., Ltd. has completed clinical trial enrollment for its "interventional ventricular assist system," which has been approved for expedited review by the National Medical Products Administration [5]

Core Viewpoint - The company has recently launched a new functional framework glasses called "Compound Control" aimed at myopia prevention, while maintaining a cautious approach towards children's eye monitoring glasses due to past experiences [1] Company Summary - The company is focusing on the development of eye care technologies rather than solely monitoring devices for children [1]

Core Insights - The company OPPLE Optoelectronics reported that as of October 10, 2025, the total number of shareholders is 61,458 [2] Company Summary - OPPLE Optoelectronics has engaged with investors through an interactive platform, providing updates on shareholder numbers [2] - The company is actively communicating with its investors, indicating a focus on transparency and shareholder engagement [2]

Core Viewpoint - Oupeng Vision reported that as of October 10, 2025, the total number of shareholders is 61,458 [2] Company Summary - Oupeng Vision has a total of 61,458 shareholders as of the specified date [2]

Core Viewpoint - The company OPPLE Optoelectronics will disclose its third-quarter report on October 25, providing insights into its operational performance [2] Summary by Categories - **Company Announcement** - OPPLE Optoelectronics will release its third-quarter financial report on October 25 [2] - Investors are encouraged to review the operational details in the upcoming report [2]

Core Insights - The company, Opcon Vision, is actively monitoring new technological developments related to vision health and conducts regular evaluations to identify suitable projects for timely initiation [2] Group 1 - The company is committed to tracking advancements in vision health technology [2] - Regular discussions and assessments are held to evaluate new technologies [2] - Suitable projects will be promptly initiated based on evaluations [2]

Core Viewpoint - The company, Opcon Vision (300595.SZ), will disclose its third-quarter report on October 25, and investors are advised to check the report for specific operational details [2] Group 1 - As of October 10, 2025, the total number of shareholders for the company is 61,458 [2]

Core Viewpoint - The stock of Opcon Vision has shown fluctuations in recent trading days, with a slight increase on September 30, 2023, despite a year-to-date decline of 9.11% [1][2]. Company Overview - Opcon Vision Technology Co., Ltd. was established on October 26, 2000, and went public on January 17, 2017. The company is located in Hefei, Anhui Province, and specializes in the research, production, and sales of optical products and related services [2]. - The main revenue sources for the company include: hard contact lenses (40.86%), other optical products and technical services (21.52%), medical services (19.89%), nursing products (12.57%), non-optical products (4.60%), and other (0.55%) [2]. Financial Performance - For the first half of 2025, Opcon Vision reported a revenue of 871 million yuan, a year-on-year decrease of 1.42%, and a net profit attributable to shareholders of 250 million yuan, down 22.93% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 897 million yuan in dividends, with 526 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Opcon Vision was 61,000, a decrease of 1.56% from the previous period. The average circulating shares per person increased by 1.58% to 10,957 shares [2]. - Major institutional shareholders include Huabao Zhongzheng Medical ETF, Yifangda Growth Enterprise Board ETF, and Southern Zhongzheng 500 ETF, with all showing increases in their holdings compared to the previous period [3].

Group 1 - The core viewpoint of the article is that the new national centralized procurement policy does not prioritize lowest price procurement, which may enhance the competitive edge of companies with advanced technologies like DK185 [2] - The company, Opcon Vision (300595.SZ), indicated that its DK185 product has not yet participated in centralized procurement but is experiencing good market promotion and gradually increasing sales [2]